
112.76 Delayed Data As of Oct 02 | ![]() Today’s Change | 95.50 Today|||52-Week Range 188.99 | -24.94% Year-to-Date |
3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street Oct 01 / MotleyFool.com - Paid Partner Content | Undervalued Biotech Stocks Shine: Pfizer and BioNTech Show Robust Resilience Sep 28 / GuruFocus News - Paid Partner Content |
Why Pfizer and BioNTech Stocks Zoomed Higher Today Sep 29 / MotleyFool.com - Paid Partner Content | Undervalued Biotech Stocks Shine: Pfizer and BioNTech Show Resilience Sep 28 / GuruFocus News - Paid Partner Content |
Why CureVac Stock Plunged Today Sep 29 / MotleyFool.com - Paid Partner Content | With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock? Sep 20 / MotleyFool.com - Paid Partner Content |
Previous close | 108.64 |
Today’s open | 108.57 |
Day’s range | 108.24 - 113.04 |
Volume | 51,404 |
Average volume (3 months) | 670,334 |
Market cap | $26.1B |
Earnings growth (last year) | -18.26% |
Earnings growth (this year) | -87.32% |
Earnings growth (next 5 years) | -57.02% |
Revenue growth (last year) | -18.89% |
P/E ratio | 6.0 |
Price/Sales | 2.06 |
Price/Book | 1.24 |
No competitors data available. |
Next reporting date | November 6, 2023 |
EPS forecast (this quarter) | $1.09 |
Annual revenue (last year) | $18.2B |
Annual profit (last year) | $9.9B |
Net profit margin | 54.50% |
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |